Abstract
The antiarthritic potential of two different acyclic nucleotide analogs, i.e. 9-(2-phosphonomethoxyethyl)adenine (PMEA), its bis(pivaloyloxymethyl)ester (Bis-POM-PMEA), and 1-( S)-(3-hydroxy-2-phosphonomethoxyethyl) cytosine (HPMPC) was investigated in the rat model of mycobacterial adjuvant-induced arthritis. With dependence on the dose, timing and route of administration, as well as on the genetic constitution of the arthritis-prone animals, PMEA was able to delay the onset, and substantially reduce or nearly completely inhibit the development of arthritic paw swelling. HPMPC was less active in this model. As compared with PMEA, its prodrug, Bis-POM-PMEA, expressed much more pronounced beneficial effects after both oral and i.p. administration.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
